Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
Cell Death Dis
.
2024 Jul 24;15(7):526.
doi: 10.1038/s41419-024-06878-1.
Authors
G S Choudhary
1
2
,
S Al-Harbi
1
,
S Mazumder
1
,
B T Hill
3
,
M R Smith
3
,
J Bodo
4
,
E D Hsi
4
,
A Almasan
5
Affiliations
1
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
2
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
3
Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
4
Department of Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA.
5
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. almasaa@ccf.org.
PMID:
39048569
PMCID:
PMC11269561
DOI:
10.1038/s41419-024-06878-1
No abstract available
Publication types
Published Erratum